Top NYC, NY Social Impact Companies With Best Stability & Growth (155)

Strong Market Position & Advantage: Headway is often characterized as a leader among insurance‑enabled mental‑health provider networks, with national footprint and a large active provider network cited. The notion that “largest” depends on metric still acknowledges an advantage on provider‑network scale and insurer breadth.

Market Expansion: Operations are described as live across all 50 states and D.C., with stated rollouts into Medicare Advantage and Medicaid broadening reach beyond commercial plans. Independent trade press is referenced for the national expansion and payer‑specific launches.

Investor Backing & Capital Strength: Late‑stage raises, including a 2023 Series C and a reported ~$2.3B valuation linked to 2024 fundraising, indicate strong investor conviction and resources to scale. Coverage presents these financings as signals that investors view the company as a category leader.

Strong Revenue Growth: Company disclosures and app‑store spend trackers indicate sustained, rapid revenue gains, including periods where Hinge’s revenue surpassed a key rival in certain months. Momentum continued into recent quarters, supported by higher conversion and pricing-driven monetization.

Strong Market Position & Advantage: Industry trackers consistently place Hinge among the top three dating apps in the U.S., with clear leadership in the serious/intentional dating segment and rising monetization effectiveness. Trade press notes it has at times closed the revenue gap with Bumble, reinforcing status within the leading cohort.

Market Expansion: Management highlights fast user growth in European expansion markets and strong early traction in new Latin American entries, where the app quickly climbed download ranks. Company commentary indicates continued investment in geographic rollout with growing regional leadership signals.

Investor Backing & Capital Strength: Feedback suggests Camber benefits from substantial venture support, including a recent Series B led by a top-tier investor. This capitalization is described as enabling product build‑out and go‑to‑market execution.

Market Expansion: Feedback suggests the company is broadening its footprint across many states and moving beyond behavioral health into adjacent care settings. Public materials cite multi‑state coverage and plans to enter home health, long‑term care, and substance use care.

Innovation-Driven Growth: Feedback suggests AI‑driven billing workflows and automation underpin Camber’s reported throughput and collection improvements. This technology focus appears well‑suited to complex payer rules in targeted niches.

Strong Market Position & Advantage: Extensive U.S. district presence and peer-recognized products (e.g., BrainPOP Science) indicate durable category leadership in K–8 supplemental, animated instruction. Research-based certifications and long tenure reinforce trust with district buyers.

Investor Backing & Capital Strength: The 2022 acquisition by KIRKBI (the LEGO owner) provides deep institutional backing and resources for continued product investment. Parent-company positioning of BrainPOP as a flagship education asset signals long-term support.

Product Line Growth: Ongoing updates to assessment, reporting, and literacy features alongside the expansion of BrainPOP Science point to active product development. Industry recognition such as a CODiE Award underscores momentum in the middle-school science segment.

Strong Market Position & Advantage: Industry analyses and company disclosures depict GoodRx as the leading U.S. prescription discount and price-comparison platform by scale, usage, and brand visibility. This position is reinforced by broad pharmacy acceptance and sustained revenue at national scale.

Diversified Revenue Streams: Management is expanding beyond coupons into manufacturer programs, subscriptions, telehealth, and integrated point‑of‑sale savings. Rapid growth in manufacturer solutions has begun to counterbalance softness in legacy transactions.

Strategic Partnerships: Collaborations with major drug manufacturers and PBM/pharmacy programs (e.g., insulin affordability and biosimilar cash‑price offerings, integrated savings at checkout) extend distribution and deepen ecosystem integration. These relationships enhance consumer access and relevance with pharma and retail stakeholders.

Investor Backing & Capital Strength: Public reporting indicates a $150M Series D in March 2026 at a roughly $3B valuation with participation from top-tier investors, signaling substantial capital availability to fund expansion. Coverage across multiple industry outlets corroborates strong investor demand for the company’s infrastructure-led approach.

Strategic Partnerships: Integrations span 125+ insurers with explicit expansion into employer and health‑system channels (e.g., bridging EAP sessions to ongoing in‑network care and partnerships like Circle Medical), indicating multi‑channel distribution strength. These footholds are presented as key markers of category leadership in enablement-focused behavioral health.

Strong Revenue Growth: Reports tied to the 2026 round cite approximately $1B in annual revenue alongside 7 million visits in 2025 and a national provider network, suggesting rapid scaling in monetized utilization. Broad payer coverage and growing enterprise channels reinforce momentum in top‑line expansion.

Market Expansion: Public materials highlight growth from roughly 2,500+ to 5,500–6,000+ research sites across 50+ countries and an increase to 25+ sponsors on the platform. Feedback suggests the marketplace is scaling on both the supply (sites) and demand (sponsors) sides.

Strategic Partnerships: Named collaborations with AbbVie, Sanofi, and Moderna, plus integrations with RealTime‑Devana and CRIO, demonstrate blue‑chip adoption and expanding ecosystem reach. Feedback suggests repeated use on consequential trials and data‑sharing ties are strengthening commercial durability.

Innovation-Driven Growth: Recent launches such as AI Site Selection and AI patient pre‑screening target bottlenecks in planning, site selection, and enrollment. External recognition (e.g., Fast Company’s Most Innovative Companies with adoption more than doubling in 2023) signals momentum behind product innovation.

Investor Backing & Capital Strength: Recent financing includes a $15.5M Series A led by Costanoa with participation from Town Hall Ventures and Khosla, bringing total funding to about $20.5M and providing resources to scale operations and technology. Coverage frames the raise as fuel for national expansion, signaling strong investor confidence.

Market Expansion: Public materials describe growth from a New York launch to hundreds of schools with 15,000+ therapy sessions and new state entries (e.g., Ohio and New Jersey), alongside active hiring across roles. Messaging emphasizes rapid access and a nationwide rollout with additional payer integrations, indicating ongoing expansion momentum.

Innovation-Driven Growth: Product investment includes an AI scribe and a proprietary therapist EHR to reduce administrative burden and increase clinician throughput. The school‑integrated workflow and group therapy programs are positioned to scale access efficiently.

Strong Revenue Growth: Feedback suggests revenue and account volume expanded rapidly, with the company reporting multi‑fold increases in revenue, client count, and monthly accounts following its prior funding round. Company materials also indicate substantial debt serviced, signaling meaningful operating scale for a relatively new entrant.

Investor Backing & Capital Strength: Recent funding rounds, including a Series B, indicate continued investor support and resources to scale. Public statements frame this capital as enabling product development and go‑to‑market expansion with larger financial institutions.

Innovation-Driven Growth: An AI‑ and compliance‑first approach is presented as a core differentiator driving stronger recoveries and a more positive consumer experience. Feedback suggests this positioning has supported traction with banks, credit unions, fintechs, and debt buyers.

Profitability: Disclosures indicate Brigit surpassed $100M in revenue and reached profitability in 2023, with multiple updates noting continued profitability thereafter.

Strong Revenue Growth: Company materials show sharp 2025 momentum, including roughly $65M in Q4 revenue (over 40% year‑over‑year growth) alongside rising paying subscribers and higher ARPU.

Investor Backing & Capital Strength: The January 31, 2025 acquisition by Upbound Group (valued up to ~$460M) and management’s accretive EBITDA framing signal strengthened capital access and support for continued scaling.

Market Expansion: Multi-state therapist directories, state-specific Medicare pages, and newly formed professional entities (e.g., New York and Florida) indicate a growing geographic footprint. These signals point to operations expanding beyond a single-state pilot.

Strategic Partnerships: A collaboration with Advanced Nursing & Home Care in Maryland and Medicare in-network positioning suggest developing referral and payer channels. These relationships reinforce access to the older-adult segment Sailor targets.

Innovation-Driven Growth: An AI-native operating system for care coordination, real-time clinical insights, and billing is emphasized as a core enabler. This technology focus is positioned to free clinician time and support scalable service delivery.

Strong Revenue Growth: Reported ARR doubled year over year and is on track to at least double again, signaling robust demand and validated product‑market fit.

Profitability: The business achieved profitability before raising a Series A, indicating disciplined operations and sustainable unit economics.

Market Expansion: State-backed programs, public-sector listings, and a growing nationwide footprint across thousands of programs point to expanding distribution and geographic penetration.

Strong Revenue Growth: Recent results indicate a material rebound in revenue and originations in 2025, with management guiding to further expansion in 2026. Disclosures and coverage describe a clear return to top‑line momentum after the 2022–2023 downturn.

Profitability: Company communications show a swing back to GAAP profitability in 2025 alongside improved operating leverage. Commentary highlights continued focus on maintaining positive earnings while scaling the platform.

Strategic Partnerships: Reports describe a broad and growing base of bank, credit‑union, and private‑capital partners, including programmatic forward‑flow agreements that support origination capacity. Management emphasizes diversified funding participation across newer products as well.

Strategic Partnerships: A major asset manager invested and formed a strategic partnership in 2025 to deliver customized SMAs/UMAs, expanding distribution potential. Availability across multiple large custodians further broadens advisor access and channel reach.

Resilient & Sustainable Growth: AUM progressed from roughly $5B in early 2024 to over $8B by early 2026, indicating sustained momentum. Growth continued amid mixed ESG market currents, suggesting durable demand for personalization and tax-aware mandates.

Future-Ready Strategy: The platform emphasizes personalized direct indexing with values screens, tax and tracking‑error controls, and multi‑asset capabilities aligned with where advisor demand is headed. Industry commentary indicates advisor adoption of personalization/direct indexing is rising, reinforcing fit with future needs.

Market Expansion: Feedback suggests Revivn operates across numerous U.S. markets and European hubs, indicating broadened geographic coverage and service reach. This multi‑region presence supports delivery beyond a single‑market footprint.

Strong Hiring & Retention: Feedback suggests ongoing headcount expansion with multiple open roles across functions, signaling investment in capacity. Public team updates and active recruiting point to organizational scaling rather than contraction.

Innovation-Driven Growth: The company emphasizes a software‑enabled lifecycle platform, API integrations, and a direct buyback model that differentiates it from traditional ITAD approaches. Recent updates about expanded device retrievals and thought‑leadership content indicate continued product and process evolution.

Investor Backing & Capital Strength: High-profile investment led by GV (Google Ventures) in 2023 provided substantial capital and credibility for payer access and multi-state expansion. Feedback suggests this backing positions the company as one of the better-capitalized private players in its niche.

Market Expansion: Public hiring, local coverage, and listed locations indicate active multi-state operations with new markets launched beyond the original footprint. Evidence points to expansion efforts in states such as Florida, Ohio, Tennessee, Virginia, Washington, and Michigan.

Strategic Partnerships: The company partners with Medicaid managed care organizations to engage high-need SMI members and has cited relationships such as Molina Healthcare. This payer-aligned model and visibility in behavioral-health trade media support continued access to plan contracts.

Investor Backing & Capital Strength: Recent late-stage rounds ($50M Series C in 2024 and $75M Series D in 2025) indicate strong capital support and momentum. Feedback suggests this runway enables continued scaling across product and distribution.

Strategic Partnerships: Health‑system and financial‑advisor partnerships are emphasized, broadening distribution and enterprise reach. The company also highlights collaborations to extend value beyond enrollment.

Innovation-Driven Growth: Launch of an OTC‑benefits app and a tech‑enabled guidance platform point to product innovation that supports engagement after enrollment. Positioning around comprehensive, “unbiased” comparisons reflects a technology‑first differentiation.